Simufilam: Clinical Trials

11 trials of Simufilam, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 completed, 3 terminated. 4 Phase 1, 4 Phase 2, 3 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 14Completed 4
Phase 24Completed 3, Terminated 1
Phase 33Terminated 2, Completed 1

Follow Simufilam: new trials by email Literature Review of Simufilam trials Research Report on Simufilam

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Pharmacokinetic Study of Simufilam in Subjects With Impaired Hepatic Function
Simufilam - Hepatic Insufficiency
Phase 1CompletedCassava Sciences, Inc.272024-06-262025-01-07
Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-Simufilam Following a Single Oral Dose in Healthy Male Subjects
Simufilam - Absorption, Metabolism
Phase 1CompletedCassava Sciences, Inc.82024-02-072025-03-20
Open-label Extension for Phase 3 Clinical Trials of Simufilam
Simufilam - Alzheimer Disease
Phase 3TerminatedCassava Sciences, Inc.10812022-11-072025-05-23
Open-Label Extension of the PTI-125-04 Study in Mild-to-Moderate Alzheimer's Disease
simufilam - Alzheimer's Disease
Phase 2TerminatedCassava Sciences, Inc.902022-05-122025-08-15
Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease
Simufilam, Placebo - Alzheimer Disease
Phase 3TerminatedCassava Sciences, Inc.11252021-11-182025-09-22
Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease
Simufilam, Placebo - Alzheimer Disease
Phase 3CompletedCassava Sciences, Inc.8042021-11-032025-05-25
Food Effect and Bioequivalence Study of Simufilam Tablets in Healthy Volunteers
simufilam - Healthy Volunteers
Phase 1CompletedCassava Sciences, Inc.242021-05-042023-08-22
Simufilam (PTI-125), 100 mg, for Mild-to-moderate Alzheimer's Disease Patients
Simufilam 100 mg oral tablet, Placebo - Alzheimer Disease
Phase 2CompletedCassava Sciences, Inc.2202020-03-242025-04-22
PTI-125 for Mild-to-moderate Alzheimer's Disease Patients
Placebo oral tablet, Simufilam 100 mg tablet, Simufilam 50 mg oral tablet - Alzheimer Disease
Phase 2CompletedCassava Sciences, Inc.642019-09-092021-09-29
PTI-125 for Mild-to-moderate Alzheimer's Disease Patients
PTI-125, 100 mg tablets - Alzheimer Disease
Phase 2CompletedPain Therapeutics132019-03-072021-07-07
A Safety Study of PTI-125 in Healthy Volunteers
50 mg PTI-125, 100 mg PTI-125, 200 mg PTI-125 - Alzheimer Disease, Early Onset, Alzheimer Disease
Phase 1CompletedPain Therapeutics242017-08-182021-05-10

Conditions studied

Alzheimer Disease (8)  ·  Hepatic Insufficiency (1)

Sponsors

Cassava Sciences, Inc. (9)  ·  Pain Therapeutics (2)

Countries

United States (11)  ·  Canada (5)  ·  Australia (2)  ·  Puerto Rico (2)  ·  South Korea (2)

Top investigators

James Kupiec, MD (3)  ·  Lindsay Burns, PhD (3)  ·  Chris Cook, JD (1)  ·  George J Atiee, MD (1)  ·  Robert G Bass, MD (1)

Results publications

PMID 41500915, PMID 32920628, PMID 33188449, PMID 36934371

NIH funding

R44AG060878 (2), R44AG056166 (1), R44AG065152 (1)